NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Partnership with CDMO Alcami for Exclusive Producg Formulation
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for the treatment diseases with unmet medical needs through accelerated regulatory pathways, has entered into an agreement with Alcami Corporation, a global pharmaceutical contract development and manufacturing organization (“CDMO”). The agreement marks Tryp’s next step in the proprietary manufacturing, formulation and delivery of products for its Psilocybin-for-Neuropsychiatric Disorder, PFN(TM) (“PFN”) program. The agreement is focused on developing oral formulations for Tryp’s proprietary psilocybin active pharmaceutical ingredient (“API”), which is being manufactured by Albany Molecular Research, Inc. The announcement noted Alcami’s broad capabilities, technical expertise and ability…